Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Placenta models for HIV-1-ART-nicotine comorbidity research: advances and remaining challenges.

Cell death discovery·2026
Same author

Delayed diagnosis of vascular compression syndrome mimicking chronic gastritis: a case report.

Annals of medicine and surgery (2012)·2026
Same author

CEST MRI reveals nicotine-induced alterations in glutamate-associated molecular connectivity in the mouse brain.

Frontiers in neuroscience·2026
Same author

Translational insights into Long-COVID: evaluation of preclinical animal models along the lung-brain-immune axis with focus on Golden Syrian Hamsters.

Journal of neuroinflammation·2026
Same author

Hantavirus on the rise: clinical, virological, immunological, and public health perspectives.

Current opinion in immunology·2026
Same author

Lineage-specific CK2α deletion reshapes the transcriptome of hematopoietic stem cells toward an immune-primed state.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Aug 28, 2025

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.7K

Modular nanoarray vaccine for SARS-CoV-2.

Karen Zagorski1, Kabita Pandey2, Rajesh Rajaiah3

  • 1Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198-6025, United States.

Nanomedicine : Nanotechnology, Biology, and Medicine
|September 16, 2022
PubMed
Summary

This study introduces a novel peptide-based vaccine platform for COVID-19, offering a faster and more reliable alternative to traditional vaccines. The new platform successfully generated neutralizing antibodies against SARS-CoV-2 and the Delta variant in mice.

Keywords:
EpitopePADREPeptideSARS-CoV-2VaccineVariants of concerns (VOC)

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.6K
Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
08:07

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Published on: January 12, 2024

812

Related Experiment Videos

Last Updated: Aug 28, 2025

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.7K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.6K
Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
08:07

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Published on: January 12, 2024

812

Area of Science:

  • Immunology
  • Vaccinology
  • Nanotechnology

Background:

  • Current COVID-19 vaccines, including inactivated/attenuated viruses and mRNA platforms, face challenges in development time and efficacy in vulnerable populations.
  • Existing strategies may not provide sufficient protection for immunocompromised individuals, children, and pregnant women.

Purpose of the Study:

  • To develop a novel, modular vaccine platform using chemically synthesized peptides for improved COVID-19 vaccine development.
  • To create a self-assembling immunogen based on SARS-CoV-2 spike glycoprotein epitopes and a universal T-helper epitope.

Main Methods:

  • Designed a modular immunogen with two B-cell epitopes from SARS-CoV-2 spike protein and the PADRE T-helper epitope.
  • Conjugated epitopes to DNA probes for sequence-specific self-assembly.
  • Formulated immunogens via conjugation to gold nanoparticles or co-crystallization with epsilon inulin.
  • Immunized BALB/C mice and assessed IgG responses and virus-neutralizing titers.

Main Results:

  • The self-assembling peptide-based vaccine platform demonstrated immunogenicity in mice.
  • Formulations generated significant IgG immune responses.
  • Neutralizing antibody titers against wildtype SARS-CoV-2 and the Delta variant were observed.

Conclusions:

  • The novel modular vaccine platform is immunogenic and capable of eliciting neutralizing antibodies against SARS-CoV-2 variants.
  • This approach offers a promising alternative for rapid vaccine development and improved efficacy in diverse populations.